Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors about the appointment of US-based healthcare executive, Dr Ravi Thadhani, as an independent non-executive director to the Orthocell Board, and the Company’s plans to draw on his expertise to drive Orthocell’s Remplir™ nerve product into the US market.
